NCT04215978: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

NCT04215978
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active leptomeningeal disease; Patients with uncontrolled unstable symptomatic brain metastasis- see trial for details; Patients with prior therapy targeting OX40 (prior checkpoint inhibitor therapy is allowed)
https:/clinicaltrials.gov/show/NCT04215978

Comments are closed.

Up ↑